# Apyx Medical Corp: overview APYX · Nasdaq · CIK 719135 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/apyx.md) · [Financials](/companies/apyx/financials.md) · [Filings](/companies/apyx/filings.md) · [Insiders](/companies/apyx/insiders.md) Latest reported revenue: [$13.9m](/filings/0001437749-26-026346.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-026346). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.5](/filings/0001437749-25-033499.md) | [14.2 d](/filings/0001437749-26-007471.md) | [9.4](/filings/0001437749-26-015652.md) | [11.4](/filings/0001437749-26-026346.md) | [12.9](/filings/0001437749-25-033499.md) | [19.2 d](/filings/0001437749-26-007471.md) | [12.5](/filings/0001437749-26-015652.md) | [13.9](/filings/0001437749-26-026346.md) | | Gross margin | % | [60.5%](/filings/0001437749-25-033499.md) | [63.0% d](/filings/0001437749-26-007471.md) | [60.1%](/filings/0001437749-26-015652.md) | [62.3%](/filings/0001437749-26-026346.md) | [64.4%](/filings/0001437749-25-033499.md) | [62.6% d](/filings/0001437749-26-007471.md) | [63.5%](/filings/0001437749-26-015652.md) | [63.9%](/filings/0001437749-26-026346.md) | | Operating margin | % | [(31.6%)](/filings/0001437749-25-033499.md) | [(21.4%) d](/filings/0001437749-26-007471.md) | [(32.4%)](/filings/0001437749-26-015652.md) | [(22.6%)](/filings/0001437749-26-026346.md) | [(6.5%)](/filings/0001437749-25-033499.md) | [0.1% d](/filings/0001437749-26-007471.md) | [(7.3%)](/filings/0001437749-26-015652.md) | [(13.0%)](/filings/0001437749-26-026346.md) | | Net margin | % | [(40.9%)](/filings/0001437749-25-033499.md) | [(32.5%) d](/filings/0001437749-26-007471.md) | [(44.0%)](/filings/0001437749-26-015652.md) | [(33.2%)](/filings/0001437749-26-026346.md) | [(15.4%)](/filings/0001437749-25-033499.md) | [(6.8%) d](/filings/0001437749-26-007471.md) | [(16.9%)](/filings/0001437749-26-015652.md) | [(23.4%)](/filings/0001437749-26-026346.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(4.6) d](/filings/0001437749-25-033499.md) | [(3.2) d](/filings/0001437749-26-007471.md) | [(0.8)](/filings/0001437749-26-015652.md) | [(1.5) d](/filings/0001437749-26-026346.md) | [(4.1) d](/filings/0001437749-25-033499.md) | [(2.8) d](/filings/0001437749-26-007471.md) | [(0.6)](/filings/0001437749-26-015652.md) | [(3.6) d](/filings/0001437749-26-026346.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [48.5](/filings/0000719135-23-000018.md) | [44.5](/filings/0000719135-24-000016.md) | [52.3](/filings/0001437749-25-007521.md) | [48.1](/filings/0001437749-26-007471.md) | [52.8](/filings/0001437749-26-007471.md) | | Gross margin | % | [69.3%](/filings/0000719135-23-000018.md) | [65.4%](/filings/0000719135-24-000016.md) | [64.5%](/filings/0001437749-25-007521.md) | [61.0%](/filings/0001437749-26-007471.md) | [62.5%](/filings/0001437749-26-007471.md) | | Operating margin | % | [(29.8%)](/filings/0000719135-23-000018.md) | [(52.9%)](/filings/0000719135-24-000016.md) | [(33.0%)](/filings/0001437749-25-007521.md) | [(39.2%)](/filings/0001437749-26-007471.md) | [(12.2%)](/filings/0001437749-26-007471.md) | | Net margin | % | [(31.3%)](/filings/0000719135-23-000018.md) | [(52.1%)](/filings/0000719135-24-000016.md) | [(35.7%)](/filings/0001437749-25-007521.md) | [(48.8%)](/filings/0001437749-26-007471.md) | [(21.2%)](/filings/0001437749-26-007471.md) | | Diluted EPS | $ per share | [(0.44)](/filings/0000719135-23-000018.md) | [(0.67)](/filings/0000719135-24-000016.md) | [(0.54)](/filings/0000719135-24-000016.md) | not reported | not reported | | Free cash flow | $m | [(11.2)](/filings/0000719135-23-000018.md) | [(21.3)](/filings/0000719135-24-000016.md) | [(5.8)](/filings/0001437749-25-007521.md) | [(18.8)](/filings/0001437749-26-007471.md) | [(9.1)](/filings/0001437749-26-007471.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/apyx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $14.7m | 3,274,064 | | Added +662,840 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $14.7m | 3,270,248 | | Reduced −170,056 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $14.7m | 3,270,248 | | Reduced −170,056 | | [Archon Capital Management LLC](/funds/1398825.md) | 2026-06-30 | $11.9m | 2,644,717 | | Reduced −146,206 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.9m | 1,534,847 | | Reduced −20,425 | | [ESSEX INVESTMENT MANAGEMENT CO LLC](/funds/201772.md) | 2026-06-30 | $5.1m | 1,136,630 | | Added +235,232 | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $5.1m | 1,128,343 | | Added +23,373 | | [Silverberg Bernstein Capital Management LLC](/funds/2007880.md) | 2026-06-30 | $4.7m | 1,039,641 | | Reduced −1,429 | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $2.9m | 649,061 | | Unchanged | | [HORIZON KINETICS ASSET MANAGEMENT LLC](/funds/1056823.md) | 2026-06-30 | $2.6m | 585,000 | | Reduced −30,000 | ## Recent filings [All 688 filings](/companies/apyx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 16:19 ET | [8-K](/filings/0001437749-26-031468.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031468 | | 2026-08-07 | 16:00 ET | [8-K](/filings/0001493152-26-036557.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-036557 | | 2026-08-06 | 17:01 ET | [10-Q](/filings/0001437749-26-026346.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026346 | | 2026-08-06 | 16:09 ET | [8-K](/filings/0001437749-26-026262.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026262 | | 2026-07-24 | 17:18 ET | [8-K](/filings/0001493152-26-034619.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-034619 | | 2026-06-26 | 16:13 ET | [DEF 14A](/filings/0001437749-26-021840.md) | Proxy statement, period 2025-12-31 | 0001437749-26-021840 | | 2026-06-17 | 16:05 ET | [8-K](/filings/0001493152-26-029081.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-029081 | | 2026-05-21 | 16:23 ET | [8-K](/filings/0001437749-26-018098.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-018098 | | 2026-05-14 | 08:05 ET | [8-K](/filings/0001437749-26-016885.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-016885 | | 2026-05-11 | 08:07 ET | [8-K](/filings/0001437749-26-016000.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-016000 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-007471.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9ff7ed3d-ef50-4db7-ba79-a61df3154770) ## About the filer - CIK: 719135 - Tickers: APYX - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.